Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis

Journal of the American Society of Nephrology

Volumn 18, Issue 4, 2007, Pages 1323-1330

  Hocher, Berthold ^a   Liefeldt, Lutz ^a   Quaschning, Thomas ^c   Kalk, Philipp ^a   Ziebig, Reinhard ^a   Godes, Michael ^a   Relle, Katharina ^a   Asmus, Gernot ^b   Stasch, Johannes Peter ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Kuratorium fur Heimdialyse D M   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CANCER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL FEATURE; DISEASE MARKER; FATALITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; ISCHEMIA; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MESENTERY ISCHEMIA; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; STROKE; SURVIVAL RATE; THROMBOSIS;

EID: 34047201108     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006070684     Document Type: Article

References (41)

1. Brunner FP, Selwood NH: Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int Suppl 38: 4-15, 1992
2. Port FK: Morbidity and mortality in dialysis patients. Kidney Int 46: 1728-1737, 1994
3. Excerpts from United States Renal Data System 1999 annual data report. Am J Kidney Dis 34[Suppl 1]: 1-176, 1999
4. Byrne C, Vernon P, Cohen JJ: Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 271: 34-36, 1994
5. Morbidity and mortality of dialysis. NIH Consens Statement 11: 1-33, 1993
6. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: 112-119, 1998
7. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87-92, 2003
8. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16[Suppl 1]: 83-88, 2005
9. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J: IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 17: 863-870, 2006
10. Granger DN, Vowinkel T, Petnehazy T: Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931, 2004
11. Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 89: 1092-1103, 2001
12. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8: 247-252, 2002
13. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100: 614-620, 1999
14. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK: Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105: 2849-2854, 2002
15. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104-1111, 2003
16. Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM, Slowinski T, Sinha P, Neumayer HH: Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 14: 2329-2337, 2003
17. Hocher B, Ziebig R, Krause R, Asmus G, Neumayer HH, Liefeldt L, Stasch JP: Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 109: 2266-2268, 2004
18. Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106: 2207-2211, 2002
19. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102: 1964-1969, 2000
20. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundorfer B, Daniel WG: Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34: 1412-1418, 2003
21. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM: Soluble CD40L and cardiovascular risk in women. Circulation 104: 2266-2268, 2001
22. Schwabe RF, Engelmann H, Hess S, Fricke H: Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 117: 153-158, 1999
23. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 17[Suppl 8]: 29-32, 2002
24. Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U: Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067-1075, 2005
25. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
26. Tenaglia AN, Peters KGP, Sketch MH Jr, Annex BH: Neovascularization in atherectomy specimens from patients with unstable angina: Implications for pathogenesis of unstable angina. Am Heart J 135: 10-14, 1998
27. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
28. Richardson PD, Davies MJ, Born GV: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941-944, 1989
29. Amann K, Ritz C, Adamczak M, Ritz E: Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 18: 631-640, 2003
30. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA: Requirement for CD154 in the progression of atherosclerosis. Nat Med 5: 1313-1316, 1999
31. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ: Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 97: 7464-7469, 2000
32. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Froland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF: Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy. J Am Coll Cardiol 41: 275-279, 2003
33. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25: 1749-1754, 1995
34. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, Seo JD, Park JE: CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 92: 11-16, 1999
35. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA: The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98: 1047-1054, 2001
36. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S: Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 108: 1451-1458, 2001
37. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF: Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 268: 1066-1073, 1993
38. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90: 377-384, 2003
39. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE. Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis. Aug 26, 2006 [epub ahead of print]
40. Azar RR, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P, Germanos M, Salame E: Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151: 521.e1-521.e4, 2006
41. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Boger R, Baldus S: Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: Evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 26: 1648-1652, 2006